Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

35.64USD
18 May 2018
Change (% chg)

$-0.07 (-0.20%)
Prev Close
$35.71
Open
$35.58
Day's High
$35.74
Day's Low
$35.43
Volume
4,743,555
Avg. Vol
7,768,318
52-wk High
$39.43
52-wk Low
$31.67

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $212,424.00
Shares Outstanding(Mil.): 5,948.59
Dividend: 0.34
Yield (%): 3.82

Financials

  PFE.N Industry Sector
P/E (TTM): 19.52 28.57 32.53
EPS (TTM): 1.83 -- --
ROI: 7.91 13.08 12.63
ROE: 17.18 14.80 14.50

Johnson & Johnson scraps Alzheimer's trials on safety concerns

Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease.

18 May 2018

BRIEF-Trial shows Pfizer's Lyrica reduces seizures in children with epilepsy

* LYRICA® (PREGABALIN) ORAL SOLUTION CV PHASE 3 TRIAL IN PEDIATRIC EPILEPSY MEETS PRIMARY ENDPOINT

17 May 2018

BRIEF-Pfizer’S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By U.S. FDA

* PFIZER’S BIOSIMILAR RETACRIT® (EPOETIN ALFA-EPBX) APPROVED BY U.S. FDA

15 May 2018

Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.

15 May 2018

UPDATE 2-Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

* Shares of Amgen, JNJ fall in afternoon trading (Adds analyst comments, updates shares)

15 May 2018

FDA approves Pfizer's biosimilar of Amgen's Epogen

May 15 The U.S. Food and Drug Administration on Tuesday approved Pfizer Inc's biosimilar of Amgen Inc's anemia treatment Epogen.

15 May 2018

FDA says Mylan's EpiPen is in shortage in U.S.

U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment. | Video

09 May 2018

UPDATE 3-FDA says Mylan's EpiPen is in shortage in U.S.

May 9 U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.

09 May 2018

Drugmaker GSK rings in more change as CFO heads for exit in 2019

LONDON GlaxoSmithKline Plc , Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year.

09 May 2018

Drugmaker GSK rings in more change as CFO heads for exit in 2019

LONDON GlaxoSmithKline Plc , Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year.

09 May 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.24 +0.39
Novartis AG (NOVN.S) CHF77.00 -0.64
Merck & Co., Inc. (MRK.N) $59.14 +0.07
Roche Holding Ltd. (ROG.S) CHF224.55 +0.55
Roche Holding Ltd. (RO.S) CHF229.20 +1.00
Abbott Laboratories (ABT.N) $61.71 +0.65
Bayer AG (BAYGn.DE) €104.36 -0.14
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €66.44 +0.32
AstraZeneca plc (AZN.L) 5,241.00 -104.00

Earnings vs. Estimates